Othman Essam-Eldin R, Zhu Zeng B, Curiel David T, Khatoon Nilufar, Salem Hosam T, Khalifa Essam Al-Din M, Al-Hendy Ayman
Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA.
Am J Obstet Gynecol. 2008 Aug;199(2):117.e1-6. doi: 10.1016/j.ajog.2008.01.059.
The purpose of this study was to screen a panel of targeted adenoviruses as vectors for endometriosis gene therapy.
Endometriotic cells were obtained from subjects with ovarian endometriomas. Liver tissues were taken from donors during hepatic transplantation surgery. Human endometriotic cells and liver tissues were transfected by targeted adenoviruses expressing luciferase reporter gene. Luciferase activity that was mediated by each virus was expressed as a percentage of adenovirus serotype 5 (Ad5-CMV-luc) activity. The 2-tailed Studentt test was used to compare the adenovirus data.
In endometriotic cells, the adenovirus-RGD (Ad-RGD-luc), adenovirus under secretory leukocyte protease inhibitor promoter (Ad-SLPI-luc), and adenovirus under heparanase promoter (Ad-heparanase-luc) showed significantly higher activity, compared with the adenovirus serotype 5. In liver tissues, adenovirus-survivin (Ad-survivin-luc) and Ad-heparanase-luc had significantly lower activity, compared with adenovirus serotype 5.
Ad-heparanase-luc showed "endometriosis on, liver off" phenotype and is a promising vector for endometriosis gene therapy.